INMUNE BIO INC. Impairment of Intangible Assets (Excluding Goodwill)
INMUNE BIO INC. (INMB) reported Impairment of Intangible Assets (Excluding Goodwill) of $16.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-06
- INMUNE BIO INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- INMUNE BIO INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- INMUNE BIO INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $16.51M.
- INMUNE BIO INC. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $16.51M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $16.51M derived: sum of 3 quarters · filed 2026-08-06 | $16.51M 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $16.51M derived: sum of 2 quarters · filed 2026-08-06 | $16.51M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $16.51M 10-Q · filed 2026-08-06 | $16.51M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |